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Background Results 
Aaron Berkenwald MS4, Jacqueline Pires MS3, Pamela Ellsworth MD 
 
Nocturnal Enuresis (NE) is a common pediatric 
condition with an overall prevalence of 15-20% at 5 
years of age, with a spontaneous resolution of 
about 15% per year. 2% Of children age 15 still 
suffer from the condition and limited treatment 
options exist. Behavioral therapy achieves success 
in nearly 3/4 of children, but many families prefer 
medical intervention, especially in older children. 
Pharmacologic therapies including Desmopressin 
(DDAVP) or Imipramine are effective in 40-50% of 
children. However Imipramine has serious safety 
concerns. DDAVP in combination with a fixed dose 
anticholinergic has been shown to be useful in 
individuals who fail DDAVP alone, but still fails to 
achieve success rates greater than 60%. We 
hypothesize that by titrating up the dose of 
Oxybutynin in combination with DDAVP in 
patients who fail initial monotherapy, we will 
achieve higher rates of success with limited 
additional adverse events. We will also record 
patient demographics, associated symptoms and 
co-morbidities to determine if we can predict 
treatment success in patient subgroups.  
 
 
Objectives 
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Methods 
Ø  To investigate the efficacy of combination therapy 
(DDAVP + escalating dose Oxybutynin) in children 
with nocturnal enuresis refractory to maximal dose 
DDAVP 
Ø  Identify risk factors for monotherapy refractory NE 
Ø  Identify factors that predict success with 
combination therapy 
Conclusions 
*0 = no condition; 1 = has 
condition 
Ø  97% Overall success rate using dose titration 
Ø  No reported adverse events  
Ø  ADD/ADHD and CDVS* subgroups had statistically 
significant decreased response to monotherapy 
Ø  High monotherapy response rate in low PVR, family 
History, Psych Medication and Obese subgroups 
Ø  Age was not a predictive factor 
Ø  High dose combination therapy is safe and effective 
 
 
Ø  Bedwetting Alarm (Behavioral Therapy) ~75% 
Ø  DDAVP ~50% 
Ø  Imipramine ~40% 
Ø  DDAVP + Fixed Dose Anticholinergic 44-57% 
Treatment Options & Success Rates 
Secondary Objectives 
Primary Objective 
IRB approved retrospective analysis of NE 
patients, ages 7-18 seen at the UMMS 
Pediatric Urology Clinic from Nov, 2013 – 
Dec, 2014. 
 Inclusion Criteria 
Exclusion Criteria 
ü  Diagnosis of Primary Nocturnal Enuresis or 
Nocturnal Enuresis with Controlled* or 
resolved Daytime Voiding Symptoms (CDVS)  
ü  Treatment with at least 1 dose DDAVP 
ü  At least one follow-up visit in clinic 
 *controlled with daytime use anticholinergic 
o    Active daytime incontinence 
o    Dysfunctional voiding requiring PT 
o    Neurogenic bladder 
o    Noncompliance with therapy 
o    Failure to attend follow-up   
Inclusion 
•  Standard Bladder Education 
•  Associated Factors and Demographics Documented 
MONO 
•  Initial Monotherapy with DDAVP 
•  Starting Dose 0.2 or 0.4mg  DDAVP with 0.2mg increase 
at 2-week intervals (0.6mg max dose) 
LDCT 
•  Follow-up prior to beginning combination therapy 
•  Low Dose Combination Therapy (LDCT) 
•   0.6mg DDAVP + 5mg Oxybutynin IR  
ADCT 
•  Advanced Dose Combination Therapy (ADCT) 
•  Starting Dose 0.6mg DDAVP + 7.5mg Oxybutynin IR with 
2.5mg increase in Oxybutynin after 2-weeks without 
success (10mg max dose) 
Treatment Overview  
End Points 
•  Success on any medication was defined as 14 
consecutive nights without bed-wetting event 
•  Telephone contact occurred during the dose 
titration interval until:  
1.  Effective dose had been achieved 
2.  Maximal doses of DDAVP and oxybutynin 
had been tried  
•  Adverse events were solicited verbally during 
the phone conversation or in the clinic  
63  Patients Treated 
with DDAVP 
Monotherapy 
36 Monotherapy 
Responders 25 Non-responder 
Combination Therapy 
(DDAVP + 5mg 
Oxybutynin) 
17 Responders 8 Non-responders 
High Dose 
Combination Therapy 
(DDAVP + 7.5-10mg 
Oxybutynin) 
2 Non-responders 6 Responders 
2 Lost to follow up 
Treatment Results 
 Patient Subgroup N Response No Response 
Total 61 36 (59.0%) 25 (41.0%) 
Constipation 21 13 (61.9%) 8 (38.1%) 
Daytime Voiding Sx 18 7 (38.9%) 11 (61.1%)* 
Low PVR  20 14 (70.0%) 6 (30.0%) 
High PVR 4 2 (50.0%) 2 (50.0%) 
ADHD/ADD 16 6 (37.5%) 10 (62.5%)* 
Family History 16 11 (68.8%) 5 (31.3%) 
Psych Med 8 6 (75.0%) 2 (25.0%) 
BMI ≤ 24.9 48 27 (56.3%) 21 (43.8%) 
Overweight 5 3 (60.0%) 2 (40.0%) 
Obese 8 6 (75.0%) 2 (25.0%) 
Male  37 22 (59.5%) 15 (40.5%) 
Female 24 14 (58.3%) 10 (41.7%) !
Monotherapy Subgroup Analysis 
Combination Therapy Subgroup Analysis 
 Patient Subgroup N LDCT ADCT 
All responders 23 17 (73.9%) 6 (26.1%) 
Constipation 8 6 (75.0%) 2 (25.0%) 
Daytime Voiding Sx 10 7 (70.0%) 3 (30.0%) 
Low PVR 6 5 (83.3%) 1 (16.7%) 
High PVR 1 1 (100.0%) 0 (0.0%) 
ADHD/ADD 10 7 (70.0%) 3 (30.0%) 
Family History 4 4 (100.0%) 0.0% 
Psych Medication 2 1 (50.0%) 1 (50.0%) 
BMI ≤ 24.9 20 14 (70.0%) 6 (30.0%) 
Overweight 2 2 (100.0%) 0 (0.0%) 
Obese 1 1 (100.0%) 0 (0.0% 
Male  13 8 (61.5%) 5 (38.5%) 
Female 10 9 (90.0%) 1 (10.0%) !
*Statistically Significant Association 
CDVS = Controlled Daytime Voiding Symptoms 
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